We observed a significant reduction in the number of Ki67, Olig2- and SOX2-positive cells in the mubritinib-treated mice (Fig. 4K–M), indicating that mubritinib alters proliferation and stemness in GB tumours in vivo. Here, OLIG2 is linked to neoplasm.